Furen Pharmaceutical Group Industry Co. Ltd. provided earnings guidance for the year 2018. According to preliminary statistics of its financial department, the company predicts an increase of between RMB 431,204,200 and RMB 548,805,300, namely between RMB 823,208,000 and RMB 940,809,100 in its net profit owned by shareholders of the listed company compared with the same period of the year before, with a year-on-year increase of between 110% and 114%. The net profit belonging to shareholders of the listed company after excluding extraordinary profit and loss will increase by between RMB 725,683,200 and RMB 843,284,400, namely between RMB 747,765,200 and RMB 865,366,400 compared with the same period of the year before, with a year-on-year increase of between 3,286.31% and 3,818.87%.